A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease.
This research study is looking into a new medicine, called ARV-102, for people who have Parkinson's disease. The main goals are to understand if this new medicine is safe for people, how much of it the body takes in (absorption), and what kind of effects it might have. This is an early phase of research, sometimes called a 'Phase I' study, which means it's one of the first times the medicine is being tested in people. All adults aged 18 and over, regardless of their gender, are potentially able to take part. This type of study is really important for finding new ways to help manage Parkinson's disease in the future.
At a glance
What is this study about?
This study is investigating a new medication, known as ARV-102, for individuals living with Parkinson's disease. The main purpose of this research is to check the medicine's safety, which is always the most important first step when testing a new treatment. Researchers also want to understand how your body takes in and uses the medicine, and what effects it might have. This detailed understanding helps them work out the best way to use the medicine in the future.
This particular study is in an early stage, often called 'Phase I'. This means it's generally one of the first times this new medicine is being given to people. The information gathered from studies like this is crucial. It helps scientists learn a lot about new treatments before they can be tested in larger groups of people.
Finding new and effective treatments for Parkinson's disease is a big goal. Studies like this one are a key part of that process. By learning about new medicines early on, researchers hope to develop better ways to help people with Parkinson's disease in the future, potentially improving their quality of life.
Key takeaways
- This study is testing a new medicine called ARV-102 for Parkinson's disease.
- It's an early-stage study focused on safety and how the body handles the medicine.
- Adults aged 18 and over, of any gender, can potentially join.
- Participation involves clinic visits, taking the trial medicine, and health checks.
- You can stop taking part in the study at any time.
- The goal is to find new ways to help people with Parkinson's disease in the future.
Who may be eligible?
To be considered for this study, you need to be an adult, aged 18 years or older. This study is open to both men and women.
Beyond these basic requirements, the research team will also look at other medical details to make sure the study is safe and right for you. They will need to check your general health and your medical history. This is to ensure that taking part in the study won't put you at unnecessary risk.
The research team will have specific criteria, like what other medicines you might be taking or certain health conditions you have, that would make you either able or unable to join. They will discuss all of these details with you thoroughly to see if you are a good fit.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of Parkinson's disease?
- Are you able to attend regular clinic appointments?
- Are you willing to take a new, investigational medicine?
- Are you comfortable with blood tests and other health checks?
What does participation involve?
If you decide to take part in this study, you would likely have several visits to the clinic. These visits would involve various assessments to check your health, how the medicine is affecting your body, and to look for any side effects. These assessments could include things like blood tests, physical examinations, and possibly questionnaires about your symptoms. You would be given the study medicine, ARV-102, according to a schedule set by the researchers. The study team will explain exactly how and when to take it. There will be planned follow-up appointments after you stop taking the medicine to make sure you are well and to collect any final information. The total length of your involvement in the study will be clearly explained to you before you agree to take part.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is Parkinson's disease?
Parkinson's disease is a condition that affects the brain and can cause problems with movement, like shaking, stiffness, and slow movement.
What does 'investigational drug' mean?
An 'investigational drug' is a medicine that is still being tested and hasn't yet been approved for general use. It means researchers are trying to learn more about it.
Why is this study important for Parkinson's disease?
Studies like this help scientists learn about new potential treatments. This early research is essential for developing better ways to help people with Parkinson's disease in the future.
Will I get paid to be in the study?
Most studies don't pay you to take part, but they might cover travel expenses. You should ask the study team about this directly.
Does this mean ARV-102 will cure Parkinson's disease?
This early study is focused on safety and how the medicine works in the body, not a cure. It's a first step in understanding its potential effects.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.